PEMF for Lumbar
Spinal Stenosis.

June 2026 · 10 min read · Clinical Protocol

Lumbar Spinal Stenosis: The Silent Epidemic in Aging Populations

Lumbar spinal stenosis (LSS) is the narrowing of the spinal canal, intervertebral foramina, or lateral recesses in the lumbar spine, leading to compression of the spinal cord, cauda equina, or exiting nerve roots. It is the leading reason for lumbar spine surgery in patients over 65, yet surgical intervention carries a significant failure rate and is associated with the "failed back surgery syndrome" — a condition that creates a new, more complex pain management problem.

The hallmark symptom of LSS is neurogenic claudication: cramping, aching, or burning pain in the buttocks and legs that worsens with walking and standing (positions that extend the lumbar spine and further narrow the canal) and is relieved by sitting or forward flexion. This functional limitation — the progressive reduction of walking distance — is the primary quality-of-life driver that brings patients to clinic.

In the Philippines, LSS is severely undertreated. The combination of an aging population, limited access to spinal surgery, and a shortage of geriatric rehabilitation specialists creates a large unmet need in which PEMF can provide significant, measurable benefit — precisely in the population where pharmacological options are most constrained by comorbidities.

Why LSS Is Difficult to Treat Pharmacologically

The typical LSS patient is in their 60s–80s, with multiple comorbidities including hypertension, diabetes, and cardiovascular disease. This creates a cascade of pharmacological restrictions:

• NSAIDs: contraindicated in renal impairment, cardiovascular disease, and on anticoagulants — all common in this population
• Opioids: high fall risk in elderly, constipation, cognitive effects — generally avoided
• Gabapentin/pregabalin: effective for neuropathic component but causes sedation and gait instability, worsening fall risk
• Epidural steroids: effective short-term (6–12 weeks) but repeated injections are limited; glucose elevation is a significant risk in diabetic patients

PEMF has no systemic pharmacological effects, no drug interactions, and no contraindications related to cardiovascular disease, renal function, or diabetes. This makes it uniquely suited as either a primary or adjunctive treatment for the elderly LSS population.

The Benchmark RCT: Aydin et al. (Turkish Journal of Geriatrics)

The key randomized controlled trial for PEMF in lumbar spinal stenosis was conducted by Aydin, Paker, and Buğdayci and published in the Turkish Journal of Geriatrics. The study enrolled n=50 patients with MRI-confirmed LSS (49 completing), median age 61 years (range 51–84), randomized to active PEMF or sham placebo PEMF.

PEMF Parameters

• Frequency: 25 Hz
• Field strength: 80 gauss (8 mT)
• Session duration: 15 minutes/day
• Course: 10 sessions

Outcome Measures and Results

Patients were assessed at baseline, immediately post-treatment, and at 3-week follow-up. The active PEMF group showed statistically significant improvements (p<0.05) across all four outcome domains:

• VAS (pain): significant reduction in back and leg pain — p<0.05
• Oswestry Disability Index (ODI): significant reduction in functional disability — p<0.05
• Timed Up and Go test (TUG): significant improvement in functional mobility — p<0.05
• EQ5D-VAS (quality of life): significant improvement in general health-related QoL — p<0.05

All four improvements were sustained at the 3-week follow-up assessment — confirming that PEMF produces durable changes in LSS patients, not merely acute pain relief. The Timed Up and Go improvement is particularly clinically significant: it is a validated predictor of fall risk in elderly patients, meaning PEMF treatment may reduce fall-related injury alongside its primary pain and disability benefits.

Mechanisms: How PEMF Addresses the LSS Pathophysiology

LSS pain and neurogenic claudication arise from two converging mechanisms: (1) mechanical compression of neural structures by osteophytes, ligamentum flavum hypertrophy, and disc bulge, and (2) ischemic neurogenic inflammation triggered by walking-induced demand on compressed nerve roots. PEMF addresses mechanism (2) directly:

1. Perivertebral microcirculation enhancement — PEMF improves blood flow to the compressed cauda equina nerve roots during activity, extending the pain-free walking distance before ischemic threshold is reached.
2. Anti-inflammatory cytokine suppression — Reduction of IL-1β, TNF-α, and PGE2 in the epidural space decreases the chemical nociception that persists even at rest.
3. Ligamentum flavum softening — Chronic inflammation drives ligamentum flavum hypertrophy (the primary canal-narrowing mechanism in LSS). PEMF's suppression of fibrotic cytokines can stabilize and potentially reduce further hypertrophy.
4. Nociceptive threshold elevation — A-δ and C fiber membrane stabilization raises the pain threshold in chronically sensitized nerve roots, reducing baseline pain intensity and the hyperalgesia component of claudication pain.

Clinical Protocol for Lumbar Spinal Stenosis

• Patient positioning: prone or seated with mild forward flexion (reduces canal tension)
• Coil placement: lumbar (L2–S1) covering the stenotic segment; add sacral coil if bilateral claudication
• Frequency: 25 Hz (matching the validated RCT protocol); 10–15 Hz for predominantly neuropathic pain
• Field strength: 8–10 mT (80–100 gauss)
• Session duration: 15–30 minutes
• Course: 10 sessions minimum (as per RCT); extend to 20 sessions for moderate-severe cases
• Frequency: daily or 5x/week for the first 2 weeks; 3x/week for continuation
• Combination: most effective when combined with aquatic physiotherapy and McKenzie extension exercises — the forward flexion component of aquatic therapy synergizes with PEMF's canal decompression effect
• Maintenance: 1–2 sessions/week indefinitely for severe bilateral LSS; monitor TUG test as objective outcome

LSS Grading and PEMF Treatment Expectations

PEMF vs. Non-Surgical LSS Alternatives

The Philippine Geriatric Pain Opportunity

The Philippines has approximately 9.4 million Filipinos aged 65 and above (2024), a number projected to double by 2040. LSS prevalence in this population is estimated at 8–11%, representing approximately 750,000–1,000,000 potential patients — the majority of whom currently have no access to evidence-based non-pharmacological treatment.

Geriatric pain management clinics with PEMF capability occupy a highly defensible niche: the patient profile (elderly, high comorbidity burden, medication-constrained) maps precisely to PEMF's strengths — no drug interactions, no systemic side effects, measurable functional improvement in a population where TUG test improvement directly reduces fall risk and hospitalization cost.

In the 70+ Israeli clinic network (population: 9M) — now expanding to the Philippines — elderly spinal stenosis patients represent a high-volume, high-completion-rate segment: their pain is severe enough to drive treatment adherence, and the lack of pharmacological alternatives means PEMF is not competing with a cheaper drug but filling a genuine treatment gap.

Contraindications

Absolute: active cardiac pacemaker or neurostimulator, pregnancy (uncommon in this demographic), active epilepsy, active malignancy in the treatment field. Relative: lumbar spinal fusion hardware — assess MRI compatibility of the specific implant; most modern titanium instrumentation is non-ferromagnetic and compatible at clinical PEMF field strengths (<100 gauss). The 25 Hz, 8 mT protocol used in the LSS RCT is considered safe for patients with non-ferromagnetic spinal instrumentation.